Literature DB >> 22065979

A controversial conclusion regarding primary extranodal diffuse large B-cell lymphoma.

Seong Kyu Park, Jina Yun, Se Hyung Kim, Dae Sik Hong.   

Abstract

Entities:  

Year:  2011        PMID： 22065979      PMCID： PMC3208207          DOI： 10.5045/kjh.2011.46.3.207

Source DB:  PubMed          Journal:  Korean J Hematol        ISSN： 1738-7949


× No keyword cloud information.
  4 in total

1.  Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.

Authors:  Michael B Møller; Niels T Pedersen; Bjarne E Christensen
Journal:  Br J Haematol       Date:  2004-01       Impact factor: 6.998

2.  Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry.

Authors:  A D G Krol; S le Cessie; S Snijder; J C Kluin-Nelemans; P M Kluin; E M Noordijk
Journal:  Ann Oncol       Date:  2003-01       Impact factor: 32.976

3.  Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.

Authors:  Armando López-Guillermo; Luis Colomo; Mónica Jiménez; Francesc Bosch; Neus Villamor; Leonor Arenillas; Ana Muntañola; Silvia Montoto; Eva Giné; Dolors Colomer; Silvia Beà; Elías Campo; Emili Montserrat
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

4.  Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma.

Authors:  Geundoo Jang; Dok Hyun Yoon; Shin Kim; Dae Ho Lee; Sang-Wook Lee; Jooryung Huh; Cheolwon Suh
Journal:  Korean J Hematol       Date:  2011-06-21
  4 in total
  1 in total

1.  Clinical significance of post-treatment 18F-fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma.

Authors:  Young-Sil An; Joon-Kee Yoon; Su Jin Lee; Seong Hyun Jeong; Hyun Woo Lee
Journal:  Eur Radiol       Date:  2016-05-18       Impact factor: 5.315
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.